![UTI - Short Term Income Fund - Direct Plan - Growth Option - Regular - Latest NAV [ ₹28.5511 ], Returns, Performance, Portfolio & Returns 2023 UTI - Short Term Income Fund - Direct Plan - Growth Option - Regular - Latest NAV [ ₹28.5511 ], Returns, Performance, Portfolio & Returns 2023](https://assets1.cleartax-cdn.com/clearsave/images/1599738177_uti_mf_v4.png)
UTI - Short Term Income Fund - Direct Plan - Growth Option - Regular - Latest NAV [ ₹28.5511 ], Returns, Performance, Portfolio & Returns 2023
![ultra short-term funds: Use ultra short-term funds to stay liquid, ride rate hikes - The Economic Times ultra short-term funds: Use ultra short-term funds to stay liquid, ride rate hikes - The Economic Times](https://img.etimg.com/photo/msid-94607949,imgsize-209750/UseUltraShort-termFundstoStayLiquid%2CRideRateHikes.jpg)
ultra short-term funds: Use ultra short-term funds to stay liquid, ride rate hikes - The Economic Times
UTI Short Term Income Fund - Direct Plan - Regular plan : Overview, Performance, Portfolio | Mutual Fund | Value Research
![debt mutual funds 2023: Debt mutual funds offer muted returns in financial year 2022-23 - The Economic Times debt mutual funds 2023: Debt mutual funds offer muted returns in financial year 2022-23 - The Economic Times](https://m.economictimes.com/thumb/height-450,width-600,imgsize-11288,msid-99231489/mutual-funds.jpg)
debt mutual funds 2023: Debt mutual funds offer muted returns in financial year 2022-23 - The Economic Times
![Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial - The Lancet Infectious Diseases Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/47441e76-5dd9-4a1c-9621-5fe3a3d133b2/gr1.gif)
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial - The Lancet Infectious Diseases
![Direct Mutual Funds: Investors made more money through direct mutual funds in past decade - The Economic Times Direct Mutual Funds: Investors made more money through direct mutual funds in past decade - The Economic Times](https://img.etimg.com/thumb/msid-96723297,width-1200,height-900,imgsize-735783,overlay-etwealthmutualfunds/photo.jpg)
Direct Mutual Funds: Investors made more money through direct mutual funds in past decade - The Economic Times
![SBI Magnum Ultra Short Duration Fund Direct Plan Growth - Regular - Latest NAV [ ₹5220.07 ], Returns, Performance, Portfolio & Returns 2023 SBI Magnum Ultra Short Duration Fund Direct Plan Growth - Regular - Latest NAV [ ₹5220.07 ], Returns, Performance, Portfolio & Returns 2023](https://assets1.cleartax-cdn.com/clearsave/images/1599738119_sbi_mf_v4.png)
SBI Magnum Ultra Short Duration Fund Direct Plan Growth - Regular - Latest NAV [ ₹5220.07 ], Returns, Performance, Portfolio & Returns 2023
![Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women | Nature Microbiology Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women | Nature Microbiology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41564-022-01107-x/MediaObjects/41564_2022_1107_Fig1_HTML.png)
Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women | Nature Microbiology
![Axis Ultra Short Term Fund Direct Growth - Regular - Latest NAV [ ₹13.354 ], Returns, Performance, Portfolio & Returns 2023 Axis Ultra Short Term Fund Direct Growth - Regular - Latest NAV [ ₹13.354 ], Returns, Performance, Portfolio & Returns 2023](https://assets1.cleartax-cdn.com/clearsave/images/1599737782_axis_mf_v4.png)